Tobias Bald
Prof. Dr. Tobias Bald
  • Institut für Experimentelle Onkologie
Research topics
  • tumor immunology
  • single-cell transcriptomics
I am a tumor-immunologist studying resistance mechanism to cancer immunotherapies. For this, we use pre-clinical mouse models and patient samples together with cutting-edge technologies including single-cell transcriptomics and intra-vital imaging.
Selected publications

Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, Limmer A, Jönsson G, Hölzel M, Tüting T. (2014) Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. Cancer Discovery, doi: 10.1158/2159-8290.CD-13-0458.

Bald T, et al. (2014) Ultraviolet radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. doi: 10.1038/nature13111.

Glodde N*, Bald T*, et al. (2017) Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity. doi: 10.1016/j.immuni.2017.09.012.

Braun M, et al. (2020) CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells Immunity. doi: 10.1016/j.immuni.2020.09.010.

Tobias Bald
Prof. Dr. Tobias Bald
Wird geladen